- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03074318
Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
A Phase I/II Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To assess the safety and tolerability of the combination of trabectedin and avelumab in subjects with advanced leiomyosarcoma and liposarcoma.
II. To assess the objective response rate of advanced L-type sarcoma patients receiving the combination regimen of avelumab and trabectedin.
SECONDARY OBJECTIVE:
I. To further explore the clinical activity and safety profile of avelumab and trabectedin as a combination therapy.
OUTLINE:
Avelumab will be administered every 2 weeks. Trabectedin will be administered every 3 weeks for the first two doses (Week 1 and Week 4), and then every four weeks (Week 7, Week 11,…) moving forward. After Cycle 2 of trabectedin, dosing may extend to every 5 weeks at investigator discretion, for management of trabectedin-associated toxicity only. Delays of trabectedin beyond 5 weeks may be allowed but require written approval from the Sponsor-Investigator. On days where both drugs are scheduled to be administered, avelumab will be administered first. This will continue until unacceptable toxicity or confirmed disease progression.
After completion of study treatment, patients are followed up at 30 and 90 days, then every 12 weeks for 2 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98109
- Fred Hutch/University of Washington Cancer Consortium
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Must have a histologically confirmed diagnosis of advanced (metastatic or unresectable) soft tissue sarcoma with one of the following subtypes:
- Leiomyosarcoma
- Liposarcoma
- Subject must be clinically indicated to receive trabectedin therapy as part of routine care. Subjects may be first line, or have received any number of prior systemic therapies
- Total bilirubin level =< 1.5 x the upper limit of normal (ULN) mg/dL
- Aspartate aminotransferase (AST) =< 2.5 x ULN and alanine aminotransferase (ALT) =< 2.5 x ULN
- Alkaline phosphatase < 2.5 x ULN
- Serum creatinine =< 1.5 x ULN
- Calculated creatinine clearance >= 30 mL/min using the Cockcroft-Gault formula may be included
- Creatinine phosphokinase (CPK) =< 2.5 x ULN
- Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
- Platelet count >= 100,000/mm^3 (100 x 10^9/L)
- Hemoglobin >= 9 g/dL
- Subject must demonstrate a left ventricular ejection fraction (LVEF) > 45% by echocardiography (ECHO) or multigated acquisition scan (MUGA)
Male or non-pregnant and non-breast feeding female:
- Females of child-bearing potential must agree to use highly effective contraception without interruption from initiation of therapy and while on study medication and have a negative serum pregnancy test (beta - human chorionic gonadotropin [hCG]) result at screening and agree to ongoing pregnancy testing during the course of the study, and at the end of study treatment; a highly effective method of contraception is defined as one that results in a low failure rate (that is, < 1% per year), when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices, sexual abstinence, or a vasectomized partner
- Male subjects must practice abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study
- All ongoing toxicities related to prior therapies must be resolved to grade 1 or better (except alopecia)
- Subject must have an Eastern Cooperative Oncology Group (ECOG) performance status =< 1 or Karnofsky performance scale >= 70
- Subjects must have one or more measurable lesions, as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 assessed by computed tomography (CT) or magnetic resonance imaging (MRI)
- Subjects must have a life expectancy of >= 6 months, as determined by the treating physician
- Ability to understand and sign informed consent document
- Willingness and ability to comply with the scheduled visits, laboratory tests, and other study procedures
Exclusion Criteria:
- Known active, uncontrolled, or symptomatic central nervous system (CNS) metastases; a subject with controlled and asymptomatic CNS metastases may participate in this study; as such, the subject must have completed any prior treatment for CNS metastases >= 28 days (including radiotherapy and/or surgery) prior to the start of treatment in this study and should not be receiving chronic corticosteroid therapy in excess of 10 mg daily prednisone (or equivalent) for CNS metastases; subjects with known CNS metastases must be confirmed radiographically stable by at least one imaging study, at least 28 days from last treatment
- Receipt of any type of cytotoxic, biologic, or other systemic anticancer therapy (including investigational) within 2 weeks of enrollment
- Prior organ transplantation, including allogeneic stem cell transplantation
- Prior treatment with trabectedin
Significant acute or chronic infections including, among others:
- Known history of testing positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
- Known active infection with hepatitis B or hepatitis C
Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent:
- Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible
- Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses =< 10 mg or 10 mg equivalent prednisone per day
- Administration of steroids through a route known to result in a minimal systemic exposure (topical, intranasal, introocular, or inhalation) are acceptable
- Known severe hypersensitivity reactions to monoclonal antibodies (grade >= 3 National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v] 5.0), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)
- Pregnant or lactating females
- Known, active alcohol or drug abuse
- All other significant diseases (for example, inflammatory bowel disease, uncontrolled asthma), which, in the opinion of the investigator, might impair the subject's tolerance of trial treatment
Any vaccination within 4 weeks of the first dose of avelumab, with the following exceptions:
* Administration of inactivated vaccines, including inactivated flu vaccines, are allowable; however, they should not be given within 2 weeks prior to starting study treatment
- Clinically significant cardiovascular disease including cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), congestive heart failure with New York Heart Association (NYHA) class II or greater or serious cardiac arrhythmia requiring medication
- Severe (requiring active treatment) acute or chronic medical conditions including: colitis, inflammatory bowel disease, pneumonitis, or pulmonary fibrosis
- Recent (within the past year) or active suicidal ideation or behavior
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1 (1.5 mg/m^2 trabectedin + avelumab)
Avelumab will be administered every 2 weeks.
Trabectedin will be administered every 3 weeks for the first two doses (Week 1 and Week 4), and then every four weeks (Week 7, Week 11,…) moving forward.
After Cycle 2 of trabectedin, dosing may extend to every 5 weeks at investigator discretion, for management of trabectedin-associated toxicity only.
Delays of trabectedin beyond 5 weeks may be allowed but require written approval from the Sponsor-Investigator. On days where both drugs are scheduled to be administered, avelumab will be administered first.
This will continue until unacceptable toxicity or confirmed disease progression.
|
Given IV
Other Names:
Given IV
Other Names:
|
Experimental: Phase 1 (1.0 mg/m^2 trabectedin + avelumab)
Avelumab will be administered every 2 weeks.
Trabectedin will be administered every 3 weeks for the first two doses (Week 1 and Week 4), and then every four weeks (Week 7, Week 11,…) moving forward.
After Cycle 2 of trabectedin, dosing may extend to every 5 weeks at investigator discretion, for management of trabectedin-associated toxicity only.
Delays of trabectedin beyond 5 weeks may be allowed but require written approval from the Sponsor-Investigator. On days where both drugs are scheduled to be administered, avelumab will be administered first.
This will continue until unacceptable toxicity or confirmed disease progression.
|
Given IV
Other Names:
Given IV
Other Names:
|
Experimental: Phase 1 (1.2 mg/m^2 trabectedin + avelumab)
Avelumab will be administered every 2 weeks.
Trabectedin will be administered every 3 weeks for the first two doses (Week 1 and Week 4), and then every four weeks (Week 7, Week 11,…) moving forward.
After Cycle 2 of trabectedin, dosing may extend to every 5 weeks at investigator discretion, for management of trabectedin-associated toxicity only.
Delays of trabectedin beyond 5 weeks may be allowed but require written approval from the Sponsor-Investigator. On days where both drugs are scheduled to be administered, avelumab will be administered first.
This will continue until unacceptable toxicity or confirmed disease progression.
|
Given IV
Other Names:
Given IV
Other Names:
|
Experimental: Phase 2 (1.0 mg/m^2 trabectedin + avelumab)
Avelumab will be administered every 2 weeks.
Trabectedin will be administered every 3 weeks for the first two doses (Week 1 and Week 4), and then every four weeks (Week 7, Week 11,…) moving forward.
After Cycle 2 of trabectedin, dosing may extend to every 5 weeks at investigator discretion, for management of trabectedin-associated toxicity only.
Delays of trabectedin beyond 5 weeks may be allowed but require written approval from the Sponsor-Investigator. On days where both drugs are scheduled to be administered, avelumab will be administered first.
This will continue until unacceptable toxicity or confirmed disease progression.
|
Given IV
Other Names:
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse Events
Time Frame: up to 2 years 7 months total
|
Measured by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0.
|
up to 2 years 7 months total
|
Overall Response Rate (ORR)
Time Frame: Up to 2 years 7 months total
|
Rate of Partial Response (PR) + Complete Response (CR), which is the best response for each subject determined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for target lesions and assessed by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan.
Partial response is defined as a decrease in 30% or more in the sum of the longest diameter of target lesions, and complete response is defined as disappearance of all evaluable disease.
No subjects had a complete response on this study so the ORR represents subjects who had a partial response only.
|
Up to 2 years 7 months total
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Response
Time Frame: Up to 2 years 7 months total
|
Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Time to response is defined as the amount of time from when the subject first received study treatment (Cycle 1, Day 1) to when they achieved a partial response on trial. With such small numbers, this data is not necessarily representative of what a larger study would report. |
Up to 2 years 7 months total
|
Duration of Response
Time Frame: Up to 2 years 7 months total
|
Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Duration of response is defined as the amount of time a subject responded to study treatment with either a partial response or complete response until the date of last follow-up (if response ongoing at data cutoff) or the date until they progressed on study.
|
Up to 2 years 7 months total
|
Progression-free Survival (PFS)
Time Frame: At 12 weeks
|
Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Progression is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions, appearance of new lesions while on study, or clear growth of a non-target lesion.
|
At 12 weeks
|
Complete Response Rate (CR)
Time Frame: At 12 weeks
|
Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Complete Response is defined as disappearance of all evaluable disease.
|
At 12 weeks
|
Partial Response Rate (PR)
Time Frame: At 12 weeks
|
Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Partial response is defined as a decrease in 30% or more in the sum of the longest diameter of target lesions.
|
At 12 weeks
|
Stable Disease (SD)
Time Frame: At 12 weeks
|
Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Stable Disease is defined as neither sufficient shrinkage to qualify for a Partial Response (PR) nor sufficient increase to qualify for Progressive Disease (PD).
|
At 12 weeks
|
Clinical Benefit Rate
Time Frame: At 12 weeks
|
Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Clinical Benefit Rate is defined as the percentage of subjects who achieved a Complete Response (CR) + Partial Response (PR) + Stable Disease (SD).
|
At 12 weeks
|
Median Overall Survival (OS)
Time Frame: Up to 2 years post End of Treatment, for a total of 3 years
|
Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
|
Up to 2 years post End of Treatment, for a total of 3 years
|
Adverse Event Profile - All Treatment-Related Grade 3-5 Adverse Events
Time Frame: Up to 2 years 7 months total
|
Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0
|
Up to 2 years 7 months total
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Seth Pollack, Northwestern University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Sarcoma
- Neoplasms, Muscle Tissue
- Neoplasms, Adipose Tissue
- Leiomyosarcoma
- Liposarcoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Antineoplastic Agents, Immunological
- Avelumab
- Antibodies, Monoclonal
- Trabectedin
Other Study ID Numbers
- 9717 (Fred Hutch/University of Washington Cancer Consortium)
- P30CA015704 (U.S. NIH Grant/Contract)
- NCI-2017-00234 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- RG9217009 (Other Identifier: Fred Hutch/University of Washington Cancer Consortium)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Leiomyosarcoma
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Uterine Corpus LeiomyosarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Unresectable SarcomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Leiomyosarcoma | Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Unresectable Leiomyosarcoma | Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IIIC Uterine Corpus Leiomyosarcoma... and other conditionsUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingLocally Advanced Leiomyosarcoma | Metastatic Leiomyosarcoma | Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Unresectable Leiomyosarcoma | Uterine Corpus LeiomyosarcomaUnited States
-
Massachusetts General HospitalJazz PharmaceuticalsRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue Sarcoma | Advanced Leiomyosarcoma | Leiomyosarcoma MetastaticUnited States
-
National Cancer Institute (NCI)RecruitingLocally Advanced Uterine Corpus Leiomyosarcoma | Metastatic Uterine Corpus Leiomyosarcoma | Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Unresectable Uterine Corpus LeiomyosarcomaUnited States, Puerto Rico
-
Gachon University Gil Medical CenterMerck KGaA, Darmstadt, Germany; Chong Kun Dang Pharmaceutical Corp.RecruitingLeiomyosarcoma MetastaticKorea, Republic of
-
Sarcoma Alliance for Research through CollaborationCompletedMetastatic LeiomyosarcomaUnited States
-
National Cancer Institute (NCI)TerminatedHigh Grade Sarcoma | Metastatic Leiomyosarcoma | Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Unresectable Leiomyosarcoma | Myxofibrosarcoma | Metastatic Malignant Peripheral Nerve Sheath Tumor | Metastatic Synovial Sarcoma | Metastatic Undifferentiated... and other conditionsUnited States
-
David Liebner, MDWithdrawnLocally Advanced Leiomyosarcoma | Metastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Stage III Retroperitoneal Sarcoma AJCC v8 | Stage IIIA Retroperitoneal Sarcoma AJCC v8 | Stage IIIB Retroperitoneal Sarcoma AJCC v8 | Stage IV Retroperitoneal Sarcoma AJCC v8United States
Clinical Trials on Avelumab
-
Merck KGaA, Darmstadt, GermanyCompleted
-
Clinique Neuro-OutaouaisCompletedGlioblastoma Multiforme of BrainCanada
-
Promontory Therapeutics Inc.Pfizer; EMD SeronoCompletedNon-Small Cell Lung Cancer (NSCLC)United States, Switzerland
-
Vaccinex Inc.University of RochesterRecruitingMetastatic Pancreatic AdenocarcinomaUnited States
-
Samsung Medical CenterMerck KGaA, Darmstadt, GermanyActive, not recruitingLymphoma, Extranodal NK-T-CellKorea, Republic of
-
Merck KGaA, Darmstadt, GermanyCompletedSolid TumorsGermany
-
4SC AGMerck KGaA, Darmstadt, GermanyWithdrawn
-
AHS Cancer Control AlbertaEMD Serono; Alberta Cancer FoundationRecruitingSquamous Cell Carcinoma of the SkinCanada
-
McGill University Health Centre/Research Institute...RecruitingGastric Adenocarcinoma | Esophageal AdenocarcinomaCanada
-
PfizerNot yet recruitingUrinary Bladder Neoplasms | Bladder Cancer | Urothelial Carcinoma | Bladder TumorsCanada